F
ibrin clot formation (i.e., clotting) is the result of the conversion of fibrinogen to fibrin, the last step in the final common pathway of the clotting cascade, which is catalyzed by factor Xa (FXa) and then factor IIa (thrombin). 1 The intrinsic and extrinsic pathways both lead to activation of factor X and the final common pathway. Currently available oral anticoagulants in the United States differ in their mechanisms of action ( Figure 1 ).
The vitamin K antagonist warfarin has multiple targets in the intrinsic and extrinsic pathways; it inhibits hepatic production of the vitamin K-dependent clotting factors II, VII, IX, and X. Newer oral anticoagulants have more specific activity on a single clotting factor. These agents include the direct thrombin inhibitor dabigatran and direct FXa inhibitors (rivaroxaban and apixaban and the investigational agent edoxaban).
Warfarin
Warfarin has been available for more than 60 years, and until recently it was the only oral anticoagulant available in the United States. 1 The drug is widely used to prevent and Purpose. To describe the mechanisms of action, pharmacokinetics, and rate of bleeding complications from warfarin and target-specific oral anticoagulants; methods for assessing the risk for thromboembolism and bleeding in patients receiving oral anticoagulants or temporarily interrupting such therapy to undergo elective invasive procedures or surgery; therapeutic strategies for balancing these risks; and coagulation assays used to monitor oral anticoagulation therapy. Summary. The target-specific oral anticoagulants have a more specific mechanism of action and shorter elimination half-lives than warfarin, but the half-lives of these target-specific agents may be prolonged in patients with renal impairment or elderly patients, resulting in the potential for drug accumulation and bleeding complications. The rate of bleeding complications in the community setting may be higher than in the clinical trial setting. In patients receiving oral anticoagulants or temporarily interrupting oral anticoagulant therapy to undergo elective invasive procedures or surgery, the risks for thromboembolism and bleeding should be assessed by using validated risk scoring systems and patient stratification schemes. The time during which an oral anticoagulant should be withheld before an invasive procedure or surgery and the time until resumption of therapy after the procedure depend on the drug, risk of thrombosis, type of procedure (i.e., risk for bleeding), and patient-specific variables, especially renal function for the target-specific agents. New coagulation assays are in development for use in monitoring oral anticoagulant therapy.
Conclusion. An individualized approach is needed to balance the risks for thromboembolism and bleeding in patients receiving oral anticoagulants. Am J Health-Syst Pharm. 2013; 70(Suppl 1):S3-11 treat arterial and venous thromboembolism, but it requires frequent laboratory monitoring because of its narrow therapeutic index, and it also interacts with numerous drugs and foods.
Warfarin is the most commonly implicated medication in emergency hospitalizations of elderly Americans. 2 Bleeding is more likely to occur within the first month of therapy than later in treatment. 3 Risk factors for bleeding include a high intensity of anticoagulation (International Normalized Ratio [INR] >4.0), age 65 years or older, history of highly variable INRs, history of gastrointestinal (GI) bleeding, hypertension, cerebrovascular disease, anemia, malignancy, trauma, renal impairment, certain genetic factors (e.g., activity of cytochrome P-450 isozymes 2C9 and 4F2 and vitamin K oxide reductase complex subunit 1), certain concomitant drugs, and a long duration of warfarin therapy. 3 The time to onset and offset of the anticoagulant effect of warfarin is influenced by the elimination half-life of the R-and S-isomers of the drug (45 hours and 29 hours, respectively) and the four vitamin K-dependent clotting factors: The half-life of factor II is considerably longer than those of the other three vitamin K-dependent factors and the two isomers of the drug. This long half-life contributes to the lag between the time when the drug is initiated, the dosage is changed, or the drug is discontinued and the time when a clinical effect is observed. It can take up to 120 hours after the initiation of warfarin (or longer in slow metabolizers of the drug) to achieve a steady-state concentration of the drug (Figure 2) . 5 Conversely, it can take up to five days after warfarin discontinuation before the drug is completely eliminated.
The anticoagulant effect of warfarin is measured by the prothrombin time (PT), which reflects reduced hepatic production of factors II, V, VII, and X. 1 Because the reagents used for PT and their sensitivity vary among clinical laboratories, the INR is used to standardize and express the PT results. 6 The resumption of a normal INR value after warfarin discontinuation requires the production of active vitamin K-dependent clotting factors. Several variables can cause a delay in recovery of a normal INR. In a retrospective cohort study of 633 ambulatory patients with an INR greater than 6.0 and various indications for warfarin therapy, 232 patients (37%) had an INR of 4.0 or higher after two doses were withheld. 7 
Target-specific oral anticoagulants
The shortcomings of warfarin prompted research to develop new oral anticoagulants. Dabigatran was approved by the Food and Drug Administration (FDA) for stroke prevention in atrial fibrillation (AF) in October 2010. 8 Rivaroxaban was approved for this indication in November 2011 after first receiving FDA approval in July 2011 for prophylaxis of venous thromboembolism (VTE) in patients undergoing knee or hip replacement surgery. 9 Rivaroxaban was also approved by FDA for treatment of VTE (deep venous thrombosis [DVT] and pulmonary embolism [PE] ) in November 2012. An application for the indication of acute coronary syndrome (ACS) has been submitted to FDA; approval is pending, as the agency requested additional data from the manufacturer. 10 Apixaban is the newest targetspecific anticoagulant to become available. It was approved by FDA in December 2012 for reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. 11 Edoxaban has been evaluated for stroke prevention in AF, prevention of VTE in patients undergoing hip replacement surgery, and treatment of VTE. [12] [13] [14] It has been approved in Japan for VTE prevention after major orthopedic surgery, but plans for submission of a new drug application to FDA have not yet been announced.
All four of these target-specific oral anticoagulants are eliminated by the kidneys and can accumulate in patients with renal impairment, although the agents differ in the extent to which they rely on the kidneys for elimination (Table  1) . Dabigatran is the drug that is most dependent on renal function for elimination, and apixaban is the least dependent. Dabigatran is dialyzable; the other three targetspecific agents are unlikely to be removed by dialysis. As creatinine clearance decreases (i.e., as renal function deteriorates), the half-life of each drug and its anticoagulant effect increase because of drug accumulation, and this increases the potential for bleeding complications. The magnitude of the effect is largest for dabigatran and smallest for apixaban. These differences are important in the choice among the target-specific oral anticoagulants for patients with renal impairment.
Clinical trials comparing dabigatran, rivaroxaban, or apixaban with warfarin for stroke prevention in AF revealed important differences in the safety profiles of these agents. In the RELY and ROCKET-AF studies, there was no significant difference in major bleeding, the primary safety endpoint, between dabigatran (the larger [150 mg] of two dosages evaluated) or rivaroxaban and warfarin (p = 0. 31 and p = 0.44, respectively). 17, 18 In the ARISTOTLE study, the rate of major bleeding was 31% lower with apixaban than warfarin, a difference that is significant (p < 0.001). The rate of intracranial hemorrhage (ICH) was significantly lower with all three oral anticoagulants compared with warfarin in these three studies (p < 0.001, p = 0.02, and p < 0.001, respectively). However, the rate of major GI bleeding was significantly higher with dabigatran 150 mg and rivaroxaban than with warfarin (p < 0.001 for both comparisons), although it was not significantly different between apixaban and warfarin (p = 0.37). There appeared to be a tradeoff between the reduced risk for ICH and the increased risk for major GI bleeding when dabigatran or rivaroxaban was used instead of warfarin.
In 2011, dabigatran and warfarin were the most common prescription drugs associated with serious, disabling, or fatal injury reported to the FDA MedWatch adverse event reporting program. 20 Dabigatran accounted for 3781 serious adverse events, including 2367 cases of hemorrhage and 542 deaths. Warfarin accounted for 1106 serious adverse events, including 731 cases of hemorrhage and 72 deaths. The unexpectedly large number of reports of hemorrhage in patients receiving dabigatran could reflect differences between the clinical trial setting and the community setting, including differences in monitoring and perhaps heightened reporting because of a perception of greater safety issues with the newer target-specific oral anticoagulants than with warfarin and differences in patient populations. Most complications from dabigatran use reported to FDA occurred in elderly patients, many of whom have impaired renal function. Dabigatran dosage reduction is recommended for patients with renal impairment, and failure to make this reduction could explain hemorrhagic complications in these patients. 8 The use of any oral anticoagulant to reduce the risk for thromboembolism-whether it is warfarin or one of the target-specific agents-is accompanied by a risk for bleeding. Efforts to reduce the risk for bleeding may increase the risk for thromboembolism. An individualized approach is needed to balance these risks and minimize related morbidity and mortality.
Risk assessment
Several validated stroke risk assessment tools are available for use in patients with AF ( 23 The use of dabigatran instead of warfarin is suggested when oral anticoagulation is recommended in patients at intermediate or high risk for stroke (i.e., a CHADS 2 score of 1 or higher). No recommendations are made in the ACCP guidelines for the use of rivaroxaban or apixaban for stroke prevention in AF because these drugs were not approved by FDA for this indication at the time the guidelines were being developed. It is expected, however, that future updates in the guidelines will encompass these agents.
Guidelines from the American College of Cardiology (ACC) and American Heart Association (AHA) call for aspirin therapy for patients with no risk factors for stroke, aspirin or oral anticoagulant therapy for patients with one stroke risk factor, and oral anticoagulant therapy for patients with two or more risk factors. 24, 25 Dabigatran is an alternative to warfarin for oral anticoagulant therapy in patients without contraindications to its use, according to ACC and AHA. As with the ACCP guidelines, the ACC/AHA guidelines were published in 2011 and thus do not mention rivaroxaban or apixaban.
Updated guidelines released by the European Society of Cardiology (ESC) in August 2012 recommend use of the CHA 2 DS 2 -Vasc score (Table 2) , another point-based system for predicting stroke in patients with AF that takes into consideration the presence of vascular disease, history of thromboembolism, age 65-74 years (as well as 75 years or older), and female sex as well as the risk factors assessed in the CHADS 2 scoring system. 22, 26 The CHA 2 DS 2 -Vasc score was developed to improve upon the predictive value of the CHADS 2 score and better identify patients truly at low risk for stroke. 26 Patients with AF are considered at low, intermediate, or high risk for stroke if their CHA 2 DS 2 -Vasc score is 0, 1, or 2 or higher, respectively. No anticoagulant therapy is recommended by ESC for patients with a CHA 2 DS 2 -Vasc score of 0 (i.e., patients less than 65 years of age with lone AF). In patients with a CHA 2 DS 2 -Vasc score of 1, warfarin, a direct thrombin inhibitor (i.e., dabigatran), or an oral FXa inhibitor (i.e., rivaroxaban, apixaban) should be considered after assessing the risk of bleeding complications and considering patient preferences. Anticoagulant therapy is recommended unless contraindicated for patients with a CHA 2 DS 2 -Vasc score of 2 or higher.
Point-based scoring systems for assessing the risk for bleeding from the use of oral anticoagulants in patients with AF have also been developed and validated (Table 3) . 27, 28, 30 None of these scoring systems have yet been recommended by ACCP, ACC, or AHA, although the lack of a recommendation does not suggest that assessment of bleeding risk is not needed. The ESC recommends use of the HAS-BLED scoring system instead of the HEMORR 2 HAGES and Anticoagulation and Risk Factors in Atrial Fibrillation scoring systems because of the greater simplicity of HAS-BLED. 26, 28 A formal bleeding risk assessment is recommended by ESC for all patients with AF who The risk scoring systems in Table  2 and Table 3 were developed for patients with AF and are based on clinical data from this patient population. A similar process should be used to assess the risk for thromboembolism and bleeding in patients receiving oral anticoagulants for other indications (e.g., VTE), with tools developed for those specific indications.
Perioperative management
Oral anticoagulant therapy should be temporarily discontinued in patients undergoing an elective invasive procedure or surgery who have a high bleeding risk, for the purpose of avoiding bleeding complications; however, the risk for perioperative thromboembolism is also a major concern when anticoagulation therapy is interrupted. The risk for perioperative thromboembolism (Table 4 ) and bleeding (Table 5) should be evaluated in such patients to determine the appropriate time to discontinue and resume oral anticoagulant therapy. Although VTE is a postoperative concern in patients without indications for anticoagulation prior to surgery, arterial and venous thromboembolism is the primary concern during interruption of oral anticoagulation in patients with indications for such therapy before surgery (e.g., AF, mechanical heart valve, VTE). 31 A residual anticoagulant effect is acceptable at the time of minor invasive procedures or surgery with a low risk of bleeding, but minimal or no anticoagulant effect is desired at the time of major procedures with a high risk of bleeding or where the consequences of bleeding are particularly dire (Table 5 ). Aggressive anticoagulation is needed for patients at high risk for thromboembolism (Table  4) , and therapy with a short half-life (e.g., a low molecular weight heparin or target-specific oral anticoagulant instead of warfarin) should be considered in such patients so that it has a rapid offset of effect before the procedure and rapid onset after the procedure (i.e., minimal interruption of anticoagulation). The rate of decline in plasma concentration of a drug after discontinuation depends on the half-life. The percentage of the plasma concentration remaining after one, two, three, four, and five half-lives have elapsed is 50%, 25%, 12.5%, 6.25%, and 3.125%, respectively. When therapeutic concentrations are present and the drug is discontinued, at least four or five half-lives must elapse before the plasma concentration becomes sufficiently low to minimize the therapeutic effects. Variables that can cause a delay in recovery of a normal INR in patients receiving warfarin may increase the amount of time before surgery during which the drug should be withheld to avoid bleeding complications. Impaired renal function, which is common in the elderly, may require discontinuation of oral anticoagulants further in advance of surgery than would be necessary in patients with normal renal function to minimize the risk for bleeding.
Postoperative considerations in determining when to resume oral anticoagulant therapy include the effect of the surgery, risk of bleeding, and bowel motility. Therapy may be resumed once hemostasis has been achieved.
Warfarin should be discontinued five days before surgery and resumed approximately 12-24 hours after surgery when there is adequate hemostasis. 31 To minimize the risk of over-anticoagulation, generally the preoperative warfarin dose should be used instead of a larger dose when therapy is resumed. An alternative approach is to give a mini-loading dose for the first few days when therapy is reinitiated to cause more rapid anticoagulation, and then transition to the preoperative maintenance dose. 31 The number of doses of targetspecific oral anticoagulants that should be withheld before invasive procedures depends on the type of procedure and the patient's renal function (Table 6) , especially for dabigatran because of the importance of the kidneys in elimination of the drug. 34, 35 A larger number of doses of dabigatran should be withheld before invasive procedures in patients with moderate or severe renal impairment than in patients with mild renal impairment or normal renal function. A larger number of doses of dabigatran, rivaroxaban, and apixaban should be withheld before major surgery than before a minor procedure because of the greater risk 
High Risk (two-day risk of major bleeding 2-4%)
• Major cardiac surgery (heart valve replacement/coronary artery bypass grafting) Therapy should generally be resumed 24-48 hours after a minor procedure and 48-72 hours after major surgery. If unfractionated heparin (UFH) or low molecular weight heparin (LMWH) is used as bridging therapy in patients with atrial fibrillation, mechanical heart valve, or venous thromboembolism who are at high risk for thromboembolism, oral anticoagulant therapy with a target-specific agent should be resumed at the time when the UFH infusion is discontinued and at the time when the next scheduled dose of LMWH would have been given. b See Table 5 for procedure risk stratification for perioperative bleeding (minor procedures are associated with a low risk of perioperative bleeding, and major surgery is associated with a high risk for perioperative bleeding). Newer coagulation assays need to be developed, standardized, and validated. Endogenous thrombin potential (ETP), dilute prothrombin time (dPT), Heptest (American Diagnostica, Stamford, CT), prothrombinase-induced clotting time (PiCT), and chromogenic anti-factor IIa are among the assays in development. 6 The ETP reflects thrombin generation. The dPT is an assay with greater sensitivity than PT. The Heptest measures inhibition of endogenous FXa. The PiCT assay, which is approved by FDA for measuring the effects of unfractionated heparin and low molecular weight heparin, has been explored for use in measuring the anticoagulant effect of rivaroxaban. 6 Chromogenic anti-factor Xa and anti-factor IIa assays are potentially useful for monitoring coagulation during treatment with FXa inhibitors as well as the factor IIa inhibitor dabigatran. 6 of bleeding associated with major surgery (Table 5) .
Drug (Creatinine
Dabigatran, rivaroxaban, and apixaban should be resumed 24-48 hours after a minor procedure and 48-72 hours after major surgery, assuming that hemostasis has been achieved. In patients at high thrombosis risk in whom adequate hemostasis is achieved shortly after the end of the procedure and postoperative bleeding risk is standard, it may be reasonable to resume anticoagulation within 24 hours after surgery. Some clinicians suggest resuming therapy in a stepped dosing approach. For dabigatran, this would start with a half dose (75 mg) for the first dose and thereafter increase to the usual maintenance dose. For rivaroxaban, it would start with 10 mg then increase to the usual maintenance dose. 35 In patients with postoperative bowel paralysis, bridging with an injectable anticoagulant may be required until the patient is able to take oral anticoagulants. The rivaroxaban prescribing information contains a boxed warning that discontinuing rivaroxaban in the absence of adequate alternative anticoagulation increases the risk of thrombotic events and that if anticoagulation with rivaroxaban must be discontinued for a reason other than pathological bleeding, another anticoagulant should be administered. 9 
Measurement of anticoagulant effect
The lack of a need for routine laboratory monitoring is an advantage of the target-specific oral anticoagulants over warfarin. Nevertheless, measurement of anticoagulant activity during therapy with the targetspecific agents is potentially useful in patients undergoing invasive procedures or surgery and certain other patients and scenarios, such as the following:
• Active bleeding, • Progressive renal insufficiency, Various hematologic tests have been used to assess coagulation status, and the usefulness of these coagulation assays differs among the target-specific oral anticoagulants. The ecarin clotting time (ECT), a direct measure of thrombin generation (ecarin activates prothrombin), is the most useful laboratory test for monitoring coagulation during dabigatran therapy, but this test is not widely available in the clinical setting. 6 The thrombin time (TT), a measure of the activity of thrombin in plasma, is less useful than the ECT, but it is more widely available. The PT and INR are less useful than the TT for assessing coagulation during dabigatran therapy. The activated partial thromboplastin time (aPTT, a measure of the intrinsic and final common pathways in coagulation) is frequently used in most institutions and is sensitive to the effects of dabigatran; thus, this assay is a potential alternative until ECT becomes more widely available.
Chromogenic anti-FXa assays are useful for monitoring coagulation during rivaroxaban and apixaban therapy. 6 Although the aPTT and PT are less useful than chromogenic assays during rivaroxaban therapy, the availability of PT makes PT practical to use. The INR is not useful for monitoring coagulation during treatment with FXa inhibitors (i.e., rivaroxaban or apixaban). 6 The aPTT and PT are widely available, although not ideal, tests for monitoring the target-specific oral anticoagulants. The extent to which these anticoagulants prolong the aPTT and PT varies. 36 Dabigatran prolongs the aPTT to a greater extent and the PT to a lesser extent
